Pharaoh Neuro develops active solutions that protect the brain, working with care teams to go beyond watchful waiting, bringing active CSF management and minimally invasive brain access to critical moments in neuro care.
Neurapheresis™
Why CSF Matters
Cerebrospinal fluid is the body's natural protector of the brain and spinal cord, maintaining intracranial pressure, clearing metabolic waste, and delivering essential nutrients. When blood and breakdown products enter the CSF, the consequences can be catastrophic.
Pharaoh Neuro's Neurapheresis™ platform introduces active filtration, removing blood, blood breakdown products, and protein from the CSF. It is a new approach to CSF management, designed to protect the brain in patients with serious neurological conditions.
Neurapheresis™
Why CSF Matters
Cerebrospinal fluid is the body's natural protector of the brain and spinal cord, maintaining intracranial pressure, clearing metabolic waste, and delivering essential nutrients. When blood and breakdown products enter the CSF, the consequences can be catastrophic.
Pharaoh Neuro's Neurapheresis™ platform introduces active filtration, removing blood, blood breakdown products, and protein from the CSF. It is a new approach to CSF management, designed to protect the brain in patients with serious neurological conditions.
What’s New
PRESS RELEASE
August 2026
Pharaoh Neuro Receives FDA Breakthrough Device Designation for Neurapheresis
The designation recognizes the potential of the Neurapheresis system to address an unmet need in CSF management for patients with serious neurological conditions. It provides access to the FDA's Total Product Lifecycle Advisory Program (TAP) and Sprint process for expedited interaction during development and review.
PUBLICATION
2025
PILLAR-XT Trial Results Published
The PILLAR-XT study, led by Spiros L. Blackburn, MD, of McGovern Medical School at UTHealth Houston, demonstrated that active CSF filtration can accelerate the removal of blood and blood breakdown products from the cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage.
PRESS RELEASE
January 2026
Mike Blue Joins the Board of Directors of Pharaoh Neuro
Pharaoh Neuro, a medical device company developing active CSF solutions for neurocritical care, today announced the appointment of Mike Blue to its Board of Directors. Blue brings more than 25 years of leadership experience in medical devices.
MindsEye™ Expandable Port
"This approach lets us reach the area with minimal trauma to the brain — it has changed how we care for our patients."
Johnny Delashaw, MD
Director of Skull Base Surgery · Professor of Neurological Surgery
Meet the team
Guided by science, shaped by experience, and focused on transforming neurocritical care.
Our leadership team is committed to transforming neurocritical care through active CSF solutions, and to keeping patients at the center of every decision we make.
Amaza Reitmeier
Chief Executive Officer, Director
Dr. Nandan Lad
Chief Medical Officer & Co-Founder
Dr. Aaron McCabe
Chief Scientific & Technology Officer
Tali Neidenfeuhr
Systems Engineer
Blake Hedstrom
General Manager – MindsEye
Amaza Reitmeier
Chief Executive Officer, Director
Dr. Nandan Lad
Chief Medical Officer & Co-Founder
Dr. Aaron McCabe
Chief Scientific & Technology Officer
Tali Neidenfeuhr
Systems Engineer
Blake Hedstrom
General Manager – MindsEye
Amaza Reitmeier
Chief Executive Officer, Director
Dr. Nandan Lad
Chief Medical Officer & Co-Founder
Dr. Aaron McCabe
Chief Scientific & Technology Officer
Tali Neidenfeuhr
Systems Engineer
Blake Hedstrom
General Manager – MindsEye